Leflunomide

Leflunomide
(leh flew’ no mide)
Arava
PREGNANCY CATEGORY X
Drug Classes
Antiarthritic
Pyrimidine synthesis inhibitor
Therapeutic Actions
Reversibly inhibits the enzyme dihydroorotate dehydrogenase, which is active in the autoimmune process that leads to rheumatoid arthritis; blocking this enzyme relieves the signs and symptoms of inflammation and blocks the structural damage caused by the inflammatory response to the autoimmune process.
Indications
  • Treatment of active rheumatoid arthritis; to relieve symptoms and slow progression
  • Improvement in physical functioning in adults with active rheumatoid arthritis
Available Forms
Tablets—10, 20, 100 mg
Dosages
Adults
Loading dose, 100 mg PO daily for 3 days; maintenance dose, 20 mg PO daily. If not well tolerated or if ALT elevates to more than two times upper level of normal, may reduce to 10 mg PO daily. If elevation of ALT is between two and three times upper limit of normal, monitor closely if continued therapy is desired; if it is three times or greater than upper limit of normal, use of cholestyramine may decrease absorption; consider discontinuation.
Pediatric patients
Safety and efficacy not established.
Patients with hepatic impairment
Do not use with serious hepatic impairment. Decrease dosage and monitor patient closely with mild to moderate hepatic impairment.
Jul 21, 2016 | Posted by in NURSING | Comments Off on Leflunomide

Full access? Get Clinical Tree

Get Clinical Tree app for offline access